Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...

The United Kingdom aims to boost its life sciences profile as Aviva Capital Partners and Socius unveiled plans for a £1 ...

To REMS, or not to REMS. That, apparently, was the question for Cytokinetics, which has seen any potential approval for its ...

Tim Friede began willingly injecting himself with escalating doses of venom from 16 snake species. | Eighteen years ago, Tim ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

Scholar Rock is shaking up its executive team as it prepares to enter the commercial arena with the expected launch of spinal ...

Pliant Therapeutics will be cutting 45% of staffers as part of a “strategic restructuring of its workforce," the biotech ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

The U.S. government is putting down $500 million toward the development of a “universal” vaccine—a shot designed to protect ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its ...